Improving Sleep and PTSD Outcomes in Service Members: A Randomized Controlled Trial Examining the Long-Term Effects of an Integrated Treatment.

Behav TherApr 15, 2026 (epub)
Clinical ResearchPsychiatry

Anthony B Cifre, Annika M Myers, Yuwen Cynthia Jou et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial compared Compressed Prolonged Exposure (CPE) with Trauma Management Therapy (TMT), which combines exposure therapy with sleep hygiene and other skills, in 82 active-duty service members with PTSD. PTSD symptoms and actigraphy-based sleep were assessed through 6-month follow-up. Sleep changed little immediately after treatment in either group, but TMT was associated with better outcomes over follow-up. At 6 months, TMT showed advantages in sleep quality (g = 0.70), sleep efficiency (g = 0.51), and wake after sleep onset (g = -0.52) compared with CPE.

Key findings

  • At 3-month follow-up, TMT participants had better sleep efficiency (g = 0.24) and onset latency (g = -0.34) than CPE participants.
  • At 6-month follow-up, TMT participants had better sleep quality (g = 0.70), efficiency (g = 0.51), and wake after sleep onset (g = -0.52) than CPE participants.
  • Within both groups, poorer sleep at 6 months was correlated with greater PTSD symptom severity at that time.

Why it matters

Sleep disturbance may persist despite PTSD treatment, and this trial suggests that integrating sleep-focused components with exposure therapy can yield better objective sleep outcomes over time than exposure alone. The delayed improvements highlight the value of assessing sleep beyond the immediate posttreatment period. The concurrent association between poorer sleep and greater PTSD severity also underscores their ongoing relationship, without establishing causation.

What to keep in mind

The abstract reports follow-up only through 6 months and does not provide results beyond that period.

Source

Published in Behav Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.